An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Recruiting Observational Study
Adverse Pregnancy Outcomes Atopic Dermatitis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 49
Sex
Female
Study type
Observational
Participants needed
3,930 (estimated)
Sponsor
Regeneron Pharmaceuticals · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pr…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: * Continuous medical and pharmacy benefit coverage for at minimum 6 months prior to and including the estimated LMP * Diagnosis code indicative of AD in the period from up to 1 year prior to the estimated LMP through the end of the pregnancy Note: Other Protocol Defined Inc…
Contacts

Clinical Trials Administrator

844-734-6643

clinicaltrials@regeneron.com

CONTACT